BBOT

BridgeBio Oncology Therapeutics Inc

Aug 14 • 04:00PM ET

9.99

Dollar change +0.20
Percentage change 2.04	%

Financial • Shell Companies • USA • NASD

Scroll to Statements

Index	-	P/E	49.78	EPS (ttm)	0.20	Insider Own	26.79%	Shs Outstand	18.91M	Perf Week	-0.10%
Market Cap	234.86M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	17.21M	Perf Month	-6.46%
Enterprise Value	234.20M	PEG	-	EPS next Q	-	Inst Own	72.13%	Short Float	0.03%	Perf Quarter	-8.01%
Income	4.72M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.05	Perf Half Y	-8.60%
Sales	0.00M	P/B	1.24	EPS next Y	-	ROA	2.44%	Short Interest	0.00M	Perf YTD	-4.86%
Book/sh	8.05	P/C	355.86	EPS next 5Y	-	ROE	2.53%	52W High	11.59 -13.81%	Perf Year	-3.20%
Cash/sh	0.03	P/FCF	-	EPS past 3/5Y	- -	ROIC	2.49%	52W Low	8.50 17.53%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.95% 6.50%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.63	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.92	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.33	EPS Q/Q	-58.45%	SMA20	-2.76%	Beta	-0.16	Target Price	-
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-5.31%	Rel Volume	0.89	Prev Close	9.79
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	-5.71%	Avg Volume	89.70K	Price	9.99
IPO	Feb 09, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	80,031	Change	2.04%

Aug-06-25 07:33AM	Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics (GlobeNewswire) +8.09%
Jul-11-25 07:43AM	Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination (GlobeNewswire)
Mar-03-25 07:16AM	BridgeBio Oncology and Helix enter definitive merger agreement (Pharmaceutical Technology)
Feb-28-25 07:49AM	BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Ka-Targeting Medicines (Business Wire)
Feb-29-24 03:01AM	5 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
07:30AM	Loading…
Feb-14-24 07:30AM	Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares (Business Wire)
Feb-09-24 07:30AM	Helix Acquisition Corp. II Announces Pricing of Upsized $160 Million Initial Public Offering (Business Wire)

Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BBOT

BridgeBio Oncology Therapeutics Inc

Upgrade your FINVIZ experience